|
AOR Probiotics-3 (formerly Clinical Biotics) - 90 vcaps
The
enterobacteria contained in Clinical Biotics act in symbiosis and
promote a healthy intestinal flora. Lactic acid and butyric
acid-producing probiotics inhibit the growth of pathogenic bacteria
while promoting the growth of the beneficial Bifidobacterium
strain.
90 Vegi-Caps
AOR04219
100%
Vegetarian
SUPPLEMENT FACTS:
Serving Size: 1 capsule
| Streptococcus faecalis T-110
|
15,000,000 Organisms/Organismes
|
| Clostridium butyricum TO-A
|
500,000 Organisms/Organismes
|
| Bacillus mesentericus TO-A
|
500,000 Organisms/Organismes
|
Non-medicinal ingredients: lactose, potato
starch, polyvinyl alcohol, polyvinylpyrrolidone. Capsule: hypromellose,
water.
AOR™ guarantees that
no ingredients not listed on the label have been added to the product.
Contains no wheat, soy, gluten, corn, nuts, eggs, fish, or shellfish.
Suggested Use:
Take three capsules per day in
divided doses between meals, or as directed by a qualified health care
practitioner.
Main Applications:
Helps with digestion
Blocks
the growth of pathogenic bacteria
Helps the growth of beneficial
bacteria
Normalizes the inflammatory response
Source:
Live bacterial cultures. Contains dairy.
Cautions:
None
Pregnancy/Nursing:
Safe at recommended dose.
*These statements have not been evaluated by the Food and
Drug Administration. This product is not intended to diagnose, treat,
cure, or prevent any disease.
A Clinically Tested
Probiotic
Although associated with spoiled food and
infections, not all bacteria are harmful. As humans, we carry more
bacterial cells than human cells. Most of these bacteria are found in
our gastrointestinal tract where billions of bacteria reside in a
delicate equilibrium that is essential to our health. This mutually
beneficial relationship between enterobacteria and the human body is
important for the maturation of the immune system, for a normal
inflammatory response and for a healthy gastrointestinal tract. The
intestinal flora is also essential for digestion and produces several
important nutrients from otherwise indigestible foodstuffs.
Furthermore, healthy gut bacteria act as
a barrier by preventing the attachment of harmful bacteria to the
intestinal mucosa. Disturbances in this delicate gastrointestinal
microflora increase the susceptibility to pathogens and raise the risk
of infection and disease.
Probiotics help to reestablish and
support a normal bacterial microflora in the intestines. Clinical
Biotics is a probiotic formula that has been used clinically for more
than 50 years in Japan.
Clinical Biotics contains three
bacterial species with specific health promoting attributes:
Streptococcus
faecalis
S. faecalis is a natural resident of the human
gastrointestinal tract that produces lactic acid as a byproduct of
carbohydrate fermentation. Lactic acid reduces the gastrointestinal pH
thus preventing the growth of harmful bacteria.
Clostridium
butyricum
C. butyricum is also a natural resident of the
human gastrointestinal tract and breaks down dietary fiber into several
beneficial nutrients one of which is butyric acid. Butyric acid is an
important source of nourishment for the colonocytes (the cells of the
lower gastrointestinal tract) and reduces inflammation and intestinal
permeability.
Bacillus mesentericus
B.
mesentericus was added to Clinical Biotics to support the growth of S.
faecalis and C. butyricum as well as the growth of several strains of
the beneficial bifidobacterium species.
The bacterial strains
found in Clinical Biotics promote the growth of beneficial intestinal
microflora, inhibit the growth of harmful bacteria, and increase the
production of beneficial nutrients. Clinical Biotics is a room-stable
formula that contains bacteria shown to survive the acidity of the
stomach.
References
Horie
H, Zeisig M, Hirayama K, Midtvedt T, Moller L, Rafter J. Probiotic
mixture decreases DNA adduct formation in colonic epithelium induced by
the food mutagen 2-amino-9H-pyrido[2,3-b]indole in a human-flora
associated mouse model. Eur J Cancer Prev. 2003 Apr;12(2):101-7.
Seo G, Akimoto Y, Hamashima H,
Masuda K, Shiojima K, Sakuma C, Sasatsu M, Arai T. A new factor from
Bacillus mesentericus which promotes the growth of Bifidobacterium. Microbios.
2000;101(399):105-14.
Song ZF, Wu TX, Cai LS, Zhang LJ,
Zheng XD. Effects of dietary supplementation with clostridium
butyricum on the growth performance and humoral immune response in
Miichthys miiuy. J Zhejiang Univ Sci B. 2006 Jul;7(7):596-602.
Shimbo I, Yamaguchi T, Odaka T,
Nakajima K, Koide A, Koyama H, Saisho H. Effect of Clostridium butyricum
on fecal flora in Helicobacter pylori eradication therapy. World J
Gastroenterol. 2005 Dec 21;11(47):7520-4.
Seo G, Akimoto Y, Hamashima H,
Masuda K, Shiojima K, Sakuma C, Sasatsu M, Arai T. A new factor from
Bacillus mesentericus which promotes the growth of Bifidobacterium.
Microbios. 2000;101(399):105-14.
Rolfe RD. The role of probiotic
cultures in the control of gastrointestinal health. J Nutr. 2000
Feb;130(2S Suppl):396S-402S.
Probiotic mixture decreases DNA adduct formation in
colonic epithelium induced by the food mutagen
2-amino-9H-pyrido[2,3-b]indole in a human-flora associated mouse model.
Horie
H, Zeisig M, Hirayama K, Midtvedt T, Moller L, Rafter J. Eur J Cancer
Prev; 2003, 12(2):101-7.
Consumption of probiotic bacteria
such as bifidobacteria has been shown to reduce the risk of colon cancer
in animal models. However, the composition and metabolic activities of
the intestinal flora of experimental animals are significantly different
from those of humans. The aim of the study was to examine whether the
probiotic mixture, which consisted of Streptococcus faecalis,
Clostridium butyricum and Bacillus mesentericus, could decrease DNA
adduct formation induced by 2-amino-9H-pyrido[2,3-b]indole
(2-amino-alpha-carboline; AAC) in the colonic epithelium of a
human-flora-associated (HFA) mouse model. Ten HFA mice were divided into
a control group (n=4) and a probiotic group (n=6). The control group
was administered AAC for 3 days and sacrificed 24 h after the last dose.
The probiotic group was administered the probiotic mixture for 2 weeks
prior to the administration of AAC. Analysis of DNA adducts with the
32P-high-performance liquid chromatography method was performed on
stomach, jejunum and colonic epithelium, representing direct exposure
sites of AAC, and colon wall, liver and kidney, representing indirect
exposure sites. The mean level of the DNA adducts in the colonic
epithelium of the probiotic group was significantly lower than that of
control group, while the mean levels at the other sites did not differ
significantly between the groups. The results indicated that the
probiotic mixture could decrease the DNA adduct formation in the colonic
epithelium induced by AAC.
Effects of dietary
supplementation with clostridium butyricum on the growth performance and
humoral immune response in Miichthys miiuy.
Song
ZF, Wu TX, Cai LS, Zhang LJ, Zheng XD. J Zhejiang Univ Sci B; 2006,
7(7):596-602.
The effects of dietary supplementation with
Clostridium butyricum on growth performance and humoral immune response
in Miichthys miiuy were evaluated. One hundred and fifty Miichthys miiuy
weighing approximately 200-260 g were divided into five groups and
reared in 15 tanks with closed circuiting culture system. The animals
were fed 5 diets: basal diet only (control) or supplemented of the basal
diet with C. butyricum at doses of 10(3) (CB1), 10(5) (CB2), 10(7)
(CB3) or 10(9) (CB4) CFU/g. Compared with the control, the serum
phenoloxidase activity was significantly increased by the
supplementation (P<0.05), acid phosphatases activity was increased
significantly (P<0.05) at the doses of 10(9) CFU/g. Serum lysozyme
activity peaked at dose of 10(7) CFU/g and in the skin mucus at dose of
10(9) CFU/g. Immunoglobulin M level in the serum and skin mucus was
increased except at dose of 10(3) CFU/g (P<0.05). The growth at the
dose of 10(9) CFU/g was higher than that of the control (P<0.05). It
is concluded that supplementation of C. butyricum can mediate the
humoral immune responses and improve the growth performance in Miichthys
miiuy.
Effect of Clostridium butyricum on fecal flora in
Helicobacter pylori eradication therapy.
Shimbo I,
Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, Saisho H. World J
Gastroenterol; 2005, 11(47):7520-4.
AIM: To
investigate the effect of probiotic bacterium, Clostridium butyricum
MIYAIRI 588 strain (CBM) on the changes of the fecal flora in
Helicobacter pylori (H. pylori) treatment. METHODS: Thirty-five patients
with gastric or duodenal ulcers positive for H. pylori were randomized
either to 1 wk amoxicillin, clarithromycin, lansoprazole (Group 1) or to
the same regimen supplemented with CBM 7 d ahead of the triple therapy
(Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d
after the starting eradication therapy, and were examined intestinal
flora. Patients were required to keep a diary record of their condition.
RESULTS:
Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group
1. On the other hand, they did not decrease significantly in Group 2.
The Escherichia coli was dominant bacterium in Enterobacteriaceae, but
that was replaced by other species such as Klebsiella and Enterobacter
after eradication in Group 1. The change was suppressed in Group 2.
Abdominal symptoms were less frequent in Group 2 than in Group 1.
CONCLUSION:
The combined use of CBM reduced the changes in the intestinal flora and
decreased the incidence of gastrointestinal side effects.
A
new factor from Bacillus mesentericus which promotes the growth of
Bifidobacterium.
Seo G, Akimoto Y, Hamashima H,
Masuda K, Shiojima K, Sakuma C, Sasatsu M, Arai T.. Microbios; 2000,
101(399):105-14.
It was reported previously that
supernatants of cultures of Bacillus mesentericus TO-A promote the
growth of Bifidobacterium species. In this study, a new growth-promoting
factor, BM-1, was purified from the supernatant of such a culture and
its chemical structure was determined. BM-1 was identified as
3,3-dihydroxyazetidine, and it promoted the growth of several strains of
Bifidobacterium.
The role of probiotic cultures in the
control of gastrointestinal health.
Rolfe RD. J
Nutr; 2000, 130(2S Suppl):396S-402S.
The use of probiotics
to enhance intestinal health has been proposed for many years.
Probiotics are traditionally defined as viable microorganisms that have a
beneficial effect in the prevention and treatment of specific
pathologic conditions when they are ingested. There is a relatively
large volume of literature that supports the use of probiotics to
prevent or treat intestinal disorders. However, the scientific basis of
probiotic use has been firmly established only recently, and sound
clinical studies have begun to be published. Currently, the best-studied
probiotics are the lactic acid bacteria, particularly Lactobacillus sp.
and Bifidobacterium sp. However, other organisms used as probiotics in
humans include Escherichia coli, Streptococcus sp., Enterococcus sp.,
Bacteroides sp., Bacillus sp., Propionibacterium sp. and various fungi.
Some probiotic preparations contain mixtures of more than one bacterial
strain. Probiotics have been examined for their effectiveness in the
prevention and treatment of a diverse spectrum of gastrointestinal
disorders such as antibiotic-associated diarrhea (including Clostridium
difficile-associated intestinal disease), infectious bacterial and viral
diarrhea (including diarrhea caused by rotavirus, Shigella, Salmonella,
enterotoxigenic E. coli, Vibrio cholerae and human immunodeficiency
virus/ acquired immunodeficiency disorder, enteral feeding diarrhea,
Helicobacter pylori gastroenteritis, sucrase maltase deficiency,
inflammatory bowel disease, irritable bowel syndrome, small bowel
bacterial overgrowth and lactose intolerance. Probiotics have been found
to inhibit intestinal bacterial enzymes involved in the synthesis of
colonic carcinogens. There are many mechanisms by which probiotics
enhance intestinal health, including stimulation of immunity,
competition for limited nutrients, inhibition of epithelial and mucosal
adherence, inhibition of epithelial invasion and production of
antimicrobial substances. Probiotics represent an exciting prophylactic
and therapeutic advance, although additional investigations must be
undertaken before their role in intestinal health can be delineated
clearly.
The enterobacteria contained in Clinical Biotics act in symbiosis and promote a healthy intestinal flora. Lactic acid and butyric acid-producing probiotics inhibit the growth of pathogenic bacteria while promoting the growth of the beneficial Bifidobacte
Especially For Kids
SKU Number: AOR04219
On Sale - AOR Supplements
UPC 0062491704219
AOR Probiotics-3 (formerly Clinical Biotics) - 90 vcaps
|
AOR Advanced B Complex
|
AOR Multivitamins, Ortho-Core, Ortho-Minerals
|
|
AOR Ortho Bone, Bone Basics, Strontium Support
|
AOR Cardio Health, Cardio-Mag
|
|
AOR Antioxidants, R+SR, R Lipoic, CoQ10
|
AOR Antiaging, Resveratrol, BenaGene
|
|
AOR Ortho Adapt, Adrenal Support
|
AOR Whey Protein
|
|
AOR Curcumin, Inflammation, Joint Support
|
 View other AOR Supplements products
|
|
| | |
|
Your cart is empty.
 | |
| | |
|
|
|